Formate reduces ischemic injury in the male heart by increasing protein S-nitrosation

This study demonstrates that formate supplementation protects male hearts from ischemia/reperfusion injury by preserving tetrahydrobiopterin levels and enhancing nitric oxide synthase-dependent protein S-nitrosation.

The Gist

The Big Picture: A Gender Gap in Heart Protection

Imagine your heart is a high-performance engine. When a heart attack happens (ischemia), the engine runs out of fuel (oxygen). When the fuel comes back (reperfusion), it's like suddenly flooding a stalled engine with gas; it causes a massive explosion of sparks and smoke (oxidative stress) that damages the engine further. This is called Ischemia-Reperfusion (I/R) injury.

Scientists have long known that women's hearts are naturally better at handling this "explosion" than men's hearts. They have a built-in shield. However, men's hearts are more vulnerable and suffer more damage.

This study asks a simple question: Can we give men's hearts a "shield" to make them as tough as women's hearts?

The answer is yes, and the secret ingredient is a tiny molecule called Formate.

---

The Story of the "Missing Link"

1. The Factory and the Fuel

Think of the heart cells as a factory. To keep the factory running smoothly and prevent explosions, they need a special fuel called Formate.

• Women's Hearts: They have two excellent machines (enzymes named ADH5 and ALDH2) that are very good at making this Formate fuel. They are always well-stocked.
• Men's Hearts: These machines are much weaker or less active. They don't make enough Formate on their own. They are running on an empty tank.

The researchers found that if you pour some extra Formate directly into a man's heart (like refueling a car), it stops the damage from the heart attack. But if you do the same for a woman's heart, nothing happens—because she was already full up!

2. The "S-NO" Shield (The Body's Fire Extinguisher)

How does Formate actually save the day? It works by boosting a protective signal called Protein S-nitrosation (or SNO for short).

• The Analogy: Imagine the heart cells are covered in delicate glass windows. During a heart attack, the "smoke" (free radicals) tries to shatter these windows.
• The SNO Signal: Think of SNO as a layer of reinforced glass or a fire extinguisher that coats the windows. It stops the smoke from breaking the glass.
• The Result: Men's hearts usually have thin glass. When you add Formate, it triggers the production of more "reinforced glass" (SNO), protecting the heart from the explosion.

3. The Secret Ingredient: BH4 (The Spark Plug)

You might wonder, "How does Formate make the reinforced glass?" It turns out Formate is a key ingredient in a recycling plant inside the cell.

• The Problem: To make the "reinforced glass" (SNO), the heart needs a helper molecule called BH4. But during a heart attack, BH4 gets "rusty" (oxidized) and stops working.
• The Solution: Formate acts like a recycling truck. It helps the cell take the rusty BH4, clean it up, and turn it back into fresh, working BH4.
• The Mechanism: This recycling process requires a specific enzyme called DHFR. The study showed that if you block this recycling truck (using a drug called Methotrexate), Formate stops working. This proves that Formate saves the heart by keeping the BH4 recycling plant running.

4. The "NO" Connection

The study also found that Formate needs a specific signal called Nitric Oxide (NO) to work.

• The Analogy: Think of Formate as the gasoline, but Nitric Oxide is the spark plug that ignites it.
• If you block the spark plug (using a drug called L-NAME), the gasoline (Formate) sits there doing nothing, and the heart gets damaged. This proves that Formate doesn't work alone; it needs the heart's natural signaling system to kick in.

---

The Takeaway: Why This Matters

For Men:
This research suggests that men's hearts are naturally "under-fueled" regarding Formate. By giving them a supplement of Formate (perhaps in a future pill or IV treatment during a heart attack), we could potentially:

1. Recycle their rusty protective molecules (BH4).
2. Boost their "reinforced glass" (SNO).
3. Drastically reduce the size of the heart attack damage.

For Women:
Women already have this system working at peak efficiency, so adding more Formate doesn't help them. This explains why the treatment is specific to males.

In a Nutshell

Imagine a heart attack is a fire. Women's hearts have a sprinkler system that turns on automatically. Men's hearts have a broken sprinkler. This study discovered that Formate is the water pressure needed to fix the broken sprinkler in men's hearts, but only if the pipes (BH4 recycling) and the switch (Nitric Oxide) are working correctly.

This is a major step toward creating a specific, life-saving treatment for men suffering from heart disease.

Technical Summary

1. Problem Statement

Ischemic heart disease (IHD) is a leading cause of mortality, with reperfusion injury (damage occurring when blood flow returns to tissue after a period of ischemia) being a major clinical challenge. While females often exhibit endogenous protection against ischemia-reperfusion (I/R) injury compared to males, the mechanisms differ. Previous research established that:

• Protein S-nitrosation (SNO) is a critical cardioprotective mechanism mediated by Nitric Oxide (NO) signaling.
• Females have higher baseline SNO levels and higher activity of Alcohol Dehydrogenase 5 (ADH5) and Aldehyde Dehydrogenase 2 (ALDH2), enzymes that metabolize formaldehyde into formate.
• Loss of ADH5 abrogates female cardioprotection, which can be rescued by formate supplementation.
• The Gap: The mechanism of formate-mediated protection was unknown, and it was unclear whether exogenous formate could protect male hearts, which naturally have lower ADH5 and ALDH2 activity.

2. Methodology

The study utilized a combination of ex vivo (Langendorff-perfused hearts) and in vitro (cell culture) models using male and female mice.

• Animal Models: Wild-type (C57BL/6J) male and female mice (15–32 weeks old).
• Ex Vivo Model (Langendorff Perfusion):
  • Isolated hearts were perfused with Krebs-Henseleit buffer.
  • Protocol: 10 min equilibration $\rightarrow$ 20 min pre-treatment (Control, Formate 30 µM, L-NAME 10 µM, or combinations) $\rightarrow$ 25 min global ischemia $\rightarrow$ 90 min reperfusion.
  • Outcomes: Infarct size (TTC staining), functional recovery (LVDP), and molecular analysis (SNO, BH4, enzyme activity).
• In Vitro Models:
  • H9c2 cells: Used to assess protein SNO levels after 48h treatment with formate.
  • Neonatal Mouse Ventricular Cardiomyocytes (NMVMs): Subjected to "coverslip-induced" I/R injury (1h ischemia, 1h reperfusion) to measure cytotoxicity via Lactate Dehydrogenase (LDH) release.
• Pharmacological Interventions:
  • Formate: Sodium formate (30 µM).
  • NOS Inhibition: L-NAME (10 µM) to block Nitric Oxide Synthase.
  • DHFR Inhibition: Methotrexate (10 µM) to block Dihydrofolate Reductase (a key enzyme in One-Carbon Metabolism/BH4 recycling).
• Molecular Assays:
  • Protein SNO: Modified Biotin Switch Assay.
  • BH4/BH2 Levels: High-Performance Liquid Chromatography (HPLC) with electrochemical and fluorescence detection.
  • Enzyme Activity: ALDH2 and ADH5 activity assays via NADH consumption.

3. Key Contributions

• Sex-Specific Efficacy: Demonstrated for the first time that exogenous formate provides robust cardioprotection specifically in male hearts, whereas it offers no additional benefit to female hearts (which already possess high endogenous formate production).
• Mechanistic Elucidation: Identified that formate protects the heart by preserving Tetrahydrobiopterin (BH4) levels and enhancing protein S-nitrosation through a Nitric Oxide Synthase (NOS)-dependent pathway.
• Metabolic Link: Established a novel link between One-Carbon Metabolism (OCM) and NO signaling, suggesting formate acts as a substrate for BH4 recycling via Dihydrofolate Reductase (DHFR).

4. Key Results

A. Sex Differences in Enzyme Activity

• Male hearts exhibited significantly lower ALDH2 activity compared to females (though protein expression was similar).
• Combined with previous data showing lower ADH5 in males, this suggests male hearts have reduced endogenous formate production capacity.

B. Formate Reduces Ischemic Injury in Males

• Infarct Size: Formate treatment (30 µM) significantly reduced infarct size in male hearts subjected to I/R injury.
• Functional Recovery: Formate-treated male hearts showed significantly improved Left Ventricular Developed Pressure (LVDP) recovery.
• Female Response: Female hearts showed no significant improvement with formate, consistent with their already high endogenous protection.

C. Mechanism: NOS and Protein SNO

• In Vitro: Formate increased protein SNO levels in H9c2 cells and reduced LDH release in NMVMs. This effect was blocked by L-NAME, confirming a NOS-dependent mechanism.
• Ex Vivo: Formate significantly increased post-ischemic protein SNO levels in male hearts at 2 and 15 minutes of reperfusion.
• Inhibition: Co-administration of L-NAME with formate in male hearts abrogated the reduction in infarct size, proving NOS is essential for formate's protective effect.

D. Mechanism: BH4 Preservation and DHFR

• BH4 Dynamics: In untreated male hearts, I/R injury caused a significant drop in BH4 (active cofactor) and a rise in BH2 (oxidized form).
• Formate Effect: Formate treatment preserved BH4 levels and prevented the accumulation of BH2, maintaining a healthy BH4/BH2 ratio.
• DHFR Role: Inhibition of DHFR (using Methotrexate) blunted the cardioprotective effect of formate (trend toward significance, p=0.0624), suggesting that formate utilizes the OCM pathway to recycle BH2 back to BH4 via DHFR.
• ADH5 Activity: Contrary to the initial hypothesis that formate might inhibit ADH5, formate actually increased ADH5 activity in ischemic hearts, suggesting ADH5 upregulation is a downstream effect rather than the primary mechanism of SNO increase.

5. Significance and Conclusion

• Clinical Implication: This study identifies formate as a potent, sex-specific therapeutic candidate for preventing ischemic injury in males. Since males have lower endogenous formate production (due to lower ADH5/ALDH2 activity), they are more susceptible to I/R injury but also more responsive to formate supplementation.
• Pathway Discovery: The study elucidates a novel signaling axis: Formate $\rightarrow$ One-Carbon Metabolism (DHFR) $\rightarrow$ BH4 Recycling $\rightarrow$ NOS Coupling $\rightarrow$ Protein S-nitrosation $\rightarrow$ Cardioprotection.
• Future Directions: The findings suggest that targeting One-Carbon Metabolism to boost BH4 bioavailability could be a viable strategy for treating ischemic heart disease in men, potentially overcoming the limitations of current NO-based therapies which often fail due to BH4 depletion.

Limitations Noted: The study used a single dose of formate and methotrexate; the optimal dosing and timing for clinical translation require further investigation. Additionally, while BH4 recycling is the proposed mechanism, direct antioxidant effects of formate cannot be entirely ruled out.